Cargando…
Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett’s esophagus may not be benign
Background and study aims: Radiofrequency ablation (RFA) combined with endoscopic mucosal resection (EMR) is effective for eradicating dysplastic Barrett’s esophagus. The durability of response is reported to be variable. We aimed to determine the effectiveness and durability of RFA with or without...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
© Georg Thieme Verlag KG
2016
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988840/ https://www.ncbi.nlm.nih.gov/pubmed/27540572 http://dx.doi.org/10.1055/s-0042-109608 |
_version_ | 1782448481707753472 |
---|---|
author | Cameron, Georgina R. Desmond, Paul V. Jayasekera, Chatura S. Amico, Francesco Williams, Richard Macrae, Finlay A. Taylor, Andrew C. F. |
author_facet | Cameron, Georgina R. Desmond, Paul V. Jayasekera, Chatura S. Amico, Francesco Williams, Richard Macrae, Finlay A. Taylor, Andrew C. F. |
author_sort | Cameron, Georgina R. |
collection | PubMed |
description | Background and study aims: Radiofrequency ablation (RFA) combined with endoscopic mucosal resection (EMR) is effective for eradicating dysplastic Barrett’s esophagus. The durability of response is reported to be variable. We aimed to determine the effectiveness and durability of RFA with or without EMR for patients with dysplastic Barrett’s esophagus. Patients and methods: Patients with dysplastic Barrett’s esophagus referred to two academic hospitals were assessed with high definition white-light endoscopy, narrow-band imaging, and Seattle protocol biopsies. EMR was performed in visible lesions. RFA was performed at 3-month intervals until complete remission of dysplasia (CR-D) and intestinal metaplasia (CR-IM) was achieved. Results: In total, 137 patients received RFA (78 with EMR); 75 with over 12 months follow-up since commencing RFA. Pretreatment histology was intramucosal cancer (IMC) 21 %, high grade dysplasia (HGD) 54 %, low grade dysplasia (LGD) 25 %. CR-D rates were 88 %, 92 %, and 100 % at 1, 2, and 3 years; CR-IM rates were 69 %, 74 %, and 81 %. Kaplan–Meier analysis showed increasing probability of achieving CR-D/CR-IM over time. Of 26 patients maintaining CR-IM for > 12 months, five relapsed with intestinal metaplasia (19 %), and three with dysplasia (12 %). Recurrences occurred in patients with prior HGD/IMC, predominantly at the gastroesophageal junction (GEJ). None relapsed with cancer. Adverse events occurred in 4 % of RFA and 6.5 % of EMR procedures. Conclusions: RFA combined with EMR is effective in achieving CR-D/CR-IM in the majority of patients with dysplastic Barrett’s esophagus, with an incremental response over time. While durable in the majority, recurrent intestinal metaplasia and dysplasia, frequently occurring at the GEJ, suggest long-term surveillance is warranted in high risk groups. |
format | Online Article Text |
id | pubmed-4988840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | © Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-49888402016-08-18 Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett’s esophagus may not be benign Cameron, Georgina R. Desmond, Paul V. Jayasekera, Chatura S. Amico, Francesco Williams, Richard Macrae, Finlay A. Taylor, Andrew C. F. Endosc Int Open Background and study aims: Radiofrequency ablation (RFA) combined with endoscopic mucosal resection (EMR) is effective for eradicating dysplastic Barrett’s esophagus. The durability of response is reported to be variable. We aimed to determine the effectiveness and durability of RFA with or without EMR for patients with dysplastic Barrett’s esophagus. Patients and methods: Patients with dysplastic Barrett’s esophagus referred to two academic hospitals were assessed with high definition white-light endoscopy, narrow-band imaging, and Seattle protocol biopsies. EMR was performed in visible lesions. RFA was performed at 3-month intervals until complete remission of dysplasia (CR-D) and intestinal metaplasia (CR-IM) was achieved. Results: In total, 137 patients received RFA (78 with EMR); 75 with over 12 months follow-up since commencing RFA. Pretreatment histology was intramucosal cancer (IMC) 21 %, high grade dysplasia (HGD) 54 %, low grade dysplasia (LGD) 25 %. CR-D rates were 88 %, 92 %, and 100 % at 1, 2, and 3 years; CR-IM rates were 69 %, 74 %, and 81 %. Kaplan–Meier analysis showed increasing probability of achieving CR-D/CR-IM over time. Of 26 patients maintaining CR-IM for > 12 months, five relapsed with intestinal metaplasia (19 %), and three with dysplasia (12 %). Recurrences occurred in patients with prior HGD/IMC, predominantly at the gastroesophageal junction (GEJ). None relapsed with cancer. Adverse events occurred in 4 % of RFA and 6.5 % of EMR procedures. Conclusions: RFA combined with EMR is effective in achieving CR-D/CR-IM in the majority of patients with dysplastic Barrett’s esophagus, with an incremental response over time. While durable in the majority, recurrent intestinal metaplasia and dysplasia, frequently occurring at the GEJ, suggest long-term surveillance is warranted in high risk groups. © Georg Thieme Verlag KG 2016-08 2016-08-09 /pmc/articles/PMC4988840/ /pubmed/27540572 http://dx.doi.org/10.1055/s-0042-109608 Text en © Thieme Medical Publishers |
spellingShingle | Cameron, Georgina R. Desmond, Paul V. Jayasekera, Chatura S. Amico, Francesco Williams, Richard Macrae, Finlay A. Taylor, Andrew C. F. Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett’s esophagus may not be benign |
title | Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett’s esophagus may not be benign |
title_full | Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett’s esophagus may not be benign |
title_fullStr | Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett’s esophagus may not be benign |
title_full_unstemmed | Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett’s esophagus may not be benign |
title_short | Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett’s esophagus may not be benign |
title_sort | recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic barrett’s esophagus may not be benign |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988840/ https://www.ncbi.nlm.nih.gov/pubmed/27540572 http://dx.doi.org/10.1055/s-0042-109608 |
work_keys_str_mv | AT camerongeorginar recurrentintestinalmetaplasiaatthegastroesophagealjunctionfollowingendoscopiceradicationofdysplasticbarrettsesophagusmaynotbebenign AT desmondpaulv recurrentintestinalmetaplasiaatthegastroesophagealjunctionfollowingendoscopiceradicationofdysplasticbarrettsesophagusmaynotbebenign AT jayasekerachaturas recurrentintestinalmetaplasiaatthegastroesophagealjunctionfollowingendoscopiceradicationofdysplasticbarrettsesophagusmaynotbebenign AT amicofrancesco recurrentintestinalmetaplasiaatthegastroesophagealjunctionfollowingendoscopiceradicationofdysplasticbarrettsesophagusmaynotbebenign AT williamsrichard recurrentintestinalmetaplasiaatthegastroesophagealjunctionfollowingendoscopiceradicationofdysplasticbarrettsesophagusmaynotbebenign AT macraefinlaya recurrentintestinalmetaplasiaatthegastroesophagealjunctionfollowingendoscopiceradicationofdysplasticbarrettsesophagusmaynotbebenign AT taylorandrewcf recurrentintestinalmetaplasiaatthegastroesophagealjunctionfollowingendoscopiceradicationofdysplasticbarrettsesophagusmaynotbebenign |